Please select the option that best describes you:
Topics:
General Internal Medicine • Rheumatology • Lupus nephritis • Rituximab • Systemic lupus erythematosus • General Rheumatology • Nephrology • Glomerulonephritis • SLE • RheumMadness • Internal Medicine
In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction?
This question is part of a collaboration with RheumMadness and is specifically in reference to: Obinutuzumab in Lupus Nephritis
Answer from: at Academic Institution
B-cell directed therapies with or without a standard of care (SoC) are not regarded as first-line therapies for lupus nephritis. Following the case series of successful treatments of lupus nephritis with rituximab, the LUNAR study showed that rituximab+SoC improved immunologic parameters but no...
Sign in or Register to read more
Answer from: at Academic Institution
I agree with @Dr. @Kyttaris's previous answer (posted July 2020). In addition, the 2024 ACR Lupus Nephritis guidelines (discussed at the 2024 ACR meeting) still recommend mycophenolate (MMF) or cyclophosphamide as first-line induction therapies for lupus nephritis (LN), rather than B-cell depletion....